Vaccines by Chinese firms Sinovac Biotech and Sinopharm are being evaluated by the WHO for emergency-use licensing. A decision is expected this week. Photo: Xinhua Vaccines by Chinese firms Sinovac Biotech and Sinopharm are being evaluated by the WHO for emergency-use licensing. A decision is expected this week. Photo: Xinhua
Vaccines by Chinese firms Sinovac Biotech and Sinopharm are being evaluated by the WHO for emergency-use licensing. A decision is expected this week. Photo: Xinhua

Coronavirus: fuller picture of Chinese vaccine data but WHO group finds figures lacking for over 60s

  • Advisory group assesses vaccines by Sinopharm and Sinovac Biotech ahead of their evaluation for WHO emergency authorisation
  • Concern that not enough data is available about effects of these vaccines on elderly and medically vulnerable patients

Topic |   Coronavirus pandemic
Vaccines by Chinese firms Sinovac Biotech and Sinopharm are being evaluated by the WHO for emergency-use licensing. A decision is expected this week. Photo: Xinhua Vaccines by Chinese firms Sinovac Biotech and Sinopharm are being evaluated by the WHO for emergency-use licensing. A decision is expected this week. Photo: Xinhua
Vaccines by Chinese firms Sinovac Biotech and Sinopharm are being evaluated by the WHO for emergency-use licensing. A decision is expected this week. Photo: Xinhua
READ FULL ARTICLE